Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(18 sites)
United States
Florida Cancer Specialists, Orlando, Florida Emory Winship Cancer Institute, Atlanta, Georgia Georgia Cancer Center at Augusta University, Augusta, Georgia Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana Dana-Farber Cancer Institute, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan Roswell Park Cancer Institute, Buffalo, New York Levine Cancer Institute (LCI)- Atrium Health, Charlotte, North Carolina Duke Cancer Center/ DUMC, Durham, North Carolina Gabrail Cancer Research Center, Canton, Ohio Next Oncology, Dallas, Texas UTSW Medical Center, Dallas, Texas Oncology Consultants, Houston, Texas Next Oncology, Houston, Texas Northwest Medical Specialties, PLLC, Tacoma, Washington Australia
Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria Peter MacCallum Cancer Center, Parkville, Victoria Mater Hospital, South Brisbane